FMP
Albireo Pharma, Inc.
ALBO
NASDAQ
Inactive Equity
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
44.15 USD
0 (0%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Ronald H. W. Cooper
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A234...
CIK
0001322505
ISIN
US01345P1066
CUSIP
01345P106
Address
10 Post Office Square
Phone
857 254 5555
Country
US
Employee
130
IPO Date
May 11, 2007
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ALBO Financial Summary
CIK
0001322505
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
01345P106
ISIN
US01345P1066
Country
US
Price
44.15
Beta
1.04
Volume Avg.
566.9k
Market Cap
915.89M
Shares
-
52-Week
16.02-45.23
DCF
34.58
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-6.63
P/B
-
Website
https://www.albireopharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ALBO News
It looks like there's no news available.
